$ADAG
Adagene Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Jiangsu, China
ADAG chart
What traders are saying about $ADAG
Latest postsAdagene Inc. news
- Adagene at Guggenheim healthcare conference: CTLA-4 hopes build By Investing.com
Investing.com India ·
- Adagene Completes Phase 2 Enrollment for Muzastotug Plus Pembrolizumab in MSS Colorectal Cancer
Oncodaily ·
- Adagene Completes Enrollment in Phase 2 Muzastotug Trial
TipRanks ·
- Adagene completes enrollment in phase 2 trial of muzastotug By Investing.com
Investing.com UK ·
- Adagene expects $8M Sanofi closing, subject to conditions | ADAG SEC Filing - Form 6-K
Stock Titan ·
- Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
Yahoo Finance ·
- What Does Incyte (INCY) First Patient Dosing Mean For Its Colorectal Cancer Pipeline?
Yahoo Finance ·
- Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
Yahoo Finance ·
- Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
Yahoo Finance ·
- Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer
marketbeat.com ·
- Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts
marketbeat.com ·
- Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
Yahoo Finance ·
Adagene Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $7.7M | $103,204 | $18.1M | $9.3M |
| Net income | -$17.6M | -$33.4M | -$18.9M | -$80.0M |
| Diluted EPS | $-0.30 | $-0.59 | $-0.35 | $-0.31 |
| Total assets (year end) | $78.3M | $89.3M | $115.7M | $152.4M |
| Cash and equivalents (year end) | $74.5M | $85.2M | $109.9M | $143.8M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Adagene Inc.
- Ticker
- ADAG (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Jiangsu, China
- Incorporated in
- Cayman Islands
- Fiscal year end
- December 31
- SEC CIK
- 1818838
Frequently asked questions
What exchange is Adagene Inc. listed on?
Adagene Inc. trades on the Nasdaq under the ticker symbol ADAG.
What industry is Adagene Inc. in?
Adagene Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Adagene Inc. headquartered?
Adagene Inc.'s business address on file with the SEC is in Jiangsu, China.
When does Adagene Inc.'s fiscal year end?
Adagene Inc.'s fiscal year ends on December 31.
How much revenue did Adagene Inc. report?
Adagene Inc. reported $7.7M in revenue for calendar year 2025, according to its SEC filings.